RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

NuGEN Technologies enters NGS applications market

NuGEN Technologies, Inc., an innovator in genomic sample preparation, makes a dramatic entry into the next-generation sequencing (NGS) applications market with the strategic addition of a team of experts in NGS, the opening of a new Seattle research facility, and — by year’s end — the launch of a simplified sample preparation kit capable of working from reduced starting material for next-generation RNA-Seq.

13 Oct 2009

New mouse models resembles human ALS; may provide important tool for screening new drugs

A new mouse model of amyotrophic lateral sclerosis (ALS) closely resembles humans with the paralyzing disorder, researchers at Washington University School of Medicine in St. Louis report.

13 Oct 2009

Mouse model of ALS closely resembles humans with the paralyzing disorder, says report

A new mouse model of amyotrophic lateral sclerosis (ALS) closely resembles humans with the paralyzing disorder, researchers at Washington University School of Medicine in St. Louis report.

13 Oct 2009

New RNA repair and modification system in bacteria discovered

In new papers appearing this month in Science and the Proceedings of the National Academy of Sciences, University of Illinois biochemistry professor Raven H. Huang and his colleagues describe the first RNA repair system to be discovered in bacteria.

13 Oct 2009

LeVOCC air purification system destroys the PR8 strain of the H1N1 virus

LeVOCC, Inc. today announced that independent laboratory testing has conclusively demonstrated that the LeVOCCTM air purification system successfully destroys a strain of the H1N1 virus. Testing was conducted using the Puerto Rico 8 (PR8) strain of the H1N1 virus. This strain is an influenza A H1N1 seasonal strain and is a valid representative of all H1N1 strains.

9 Oct 2009

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.

9 Oct 2009

LeVOCC air purification system destroys H1N1 virus

LeVOCC, Inc. today announced that independent laboratory testing has conclusively demonstrated that the LeVOCC(TM) air purification system successfully destroys a strain of the H1N1 virus.

8 Oct 2009

Kylin Therapeutics receives notice of allowance for its first U.S. patent application

Officials of Kylin Therapeutics Inc., a leading RNAi company, announced that they have received a notice of allowance from the U.S. Patent and Trademark Office for its first U.S. patent application.

8 Oct 2009

NIH grants over $3.8 million to Asuragen

Asuragen, Inc. announced today that it has received over $3.8 million in new grant funding for 2009 from the Small Business Innovative Research (SBIR), Small Business Technology Transfer (STTR), and American Recovery and Reinvestment Act (ARRA) funded initiatives of the National Institutes of Health (NIH) to further its development of molecular diagnostics for oncology and genetic disease.

8 Oct 2009

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

Idera Pharmaceuticals, Inc. today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection. IMO-2125 is a novel agonist of Toll-like Receptor (TLR) 9.

7 Oct 2009

Scientists develop new molecule that can deliver genetic-based drugs into cells

Theresa M. Reineke, associate professor of chemistry in the College of Science, and colleagues in her lab at Virginia Tech and at the University of Cincinnati have developed a new molecule that can travel into cells, deliver genetic cargo, and packs a beacon so scientists can follow its movements in living systems.

7 Oct 2009

Researchers identify that KLF17 gene with Id1 gene can regulate breast cancer metastasis

Researchers at The Wistar Institute have identified a key gene (KLF17) involved in the spread of breast cancer throughout the body. They also demonstrated that expression of KLF17 together with another gene (Id1) known to regulate breast cancer metastasis accurately predicts whether the disease will spread to the lymph nodes.

6 Oct 2009

Scientists identify new interference method to target cancer cells

Professor Jo Milner and Dr Shafiq Ahmed, from the YCR P53 Research Unit in the Department of Biology, used a process called RNA interference to target the JNK2 gene in both cancer and healthy cells. The cancer cells died but the healthy cells were unaffected.

6 Oct 2009

New journal on cancer biology and genetics

SAGE announces Genes & Cancer, a monthly journal edited by Dr. Prem Reddy, founder and previous Editor-in-Chief of the prestigious and highly-ranked Oncogene.

6 Oct 2009

AVI BioPharma receives $11.5M DTRA fund to develop AVI-7012 for treating Junin virus infection

AVI BioPharma, Inc. a developer of RNA-based drugs, announced today that it has received expanded contract funding of approximately $11.5 million from the Defense Threat Reduction Agency's (DTRA) Transformational Medical Technologies Initiative (TMTI) to support development of the Investigational New Drug (IND) data package for its candidate drug, AVI-7012, to treat Junin virus infection.

5 Oct 2009

Rxi Pharmaceuticals to ring Nasdaq closing bell in NYC's Times Square

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that Tod Woolf, Ph.D., President and CEO, along with members of RXi’s management team, will ring the Nasdaq closing bell tomorrow, Tuesday, Oct 6, 2009 at the Nasdaq Marketsite in New York City’s Times Square.

5 Oct 2009

Researchers engineer antidotes for blood-thinner aptamers

Imagine a surgical patient on a blood-thinning drug who starts bleeding more than expected, and an antidote that works immediately - because the blood thinner and antidote were designed to work together. Researchers at Duke University Medical Center have engineered a way to do this for an entire, versatile class of drugs called aptamers and published their findings in Nature Medicine.

4 Oct 2009

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).

From Thermo Fisher Scientific Inc. 3 Oct 2009

New Magna Pure 96 System from Roche Applied Science

The new MagNA Pure 96 System from Roche Applied Science has been designed and engineered to meet the needs for high throughput laboratories worldwide. Its performance is based on Roche Applied Science’s 10 years experience in the development and application of glass-magnetic-particle based automated nucleic acid purification systems.

1 Oct 2009

Scarab Genomics releases new E. Coli strain

ScarabXpress is the latest strain in the multiple-deletion series (MDS) of Scarab Genomics Clean Genome® E. coli. Based on the MDS™42 strain, ScarabXpress T7lac contains a chromosomal copy of the T7 RNA polymerase gene expressed from a unique, tightly controlled lac promoter.

29 Sep 2009

RNA News and Research

Further Reading

NuGEN Technologies enters NGS applications market

New mouse models resembles human ALS; may provide important tool for screening new drugs

Mouse model of ALS closely resembles humans with the paralyzing disorder, says report

New RNA repair and modification system in bacteria discovered

LeVOCC air purification system destroys the PR8 strain of the H1N1 virus

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

LeVOCC air purification system destroys H1N1 virus

Kylin Therapeutics receives notice of allowance for its first U.S. patent application

NIH grants over $3.8 million to Asuragen

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

Scientists develop new molecule that can deliver genetic-based drugs into cells

Researchers identify that KLF17 gene with Id1 gene can regulate breast cancer metastasis

Scientists identify new interference method to target cancer cells

New journal on cancer biology and genetics

AVI BioPharma receives $11.5M DTRA fund to develop AVI-7012 for treating Junin virus infection

Rxi Pharmaceuticals to ring Nasdaq closing bell in NYC's Times Square

Researchers engineer antidotes for blood-thinner aptamers

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

New Magna Pure 96 System from Roche Applied Science

Scarab Genomics releases new E. Coli strain

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo